Subcutaneous Lidocaine Injection in Acute Herpes Zoster Neuralgia and Post-herpetic Neuralgia

NCT06882525 | Completed DMC

• 1 other identifier: E2-25-9924
• Study Type: interventional
• Target: 110
• Locations: 1 country
• Sites: 1

Brief Summary

In this study, it was aimed to compare the effect of subcutaneous lidocaine injection, which is routinely applied in pain clinic,in patients who present with pain complaints due to acute herpes zoster and post-herpetic neuralgia, and investigate its contribution to preventing the development of post-herpetic neuralgia

Conditions

Herpes Zoster; Neuralgia, Postherpetic

Keywords

Neuralgia, Postherpetic; HERPES ZOSTER; Lidocaine

Outcome Measures

Primary Outcomes (1)

• NRS , DN4

  The patients' pain scores will be assessed before treatment using the NRS (Numerical Rating Scale) and DN4 (Douleur Neuropathique en 4 Questions) pain scales. During the treatment process, patients will receive three injections, one week apart, and the NRS and DN4 pain scores will be reassessed one week after each injection.

  1st week after injection

Study Arms (1)

Patients who are referred from the dermatology clinic or voluntarily present to our pain management

ACTIVE COMPARATOR

The result of the study will provide insight into how much subcutaneous lidocaine injection, applied to patients with pain due to acute HZ and PHN, reduces pain, compare the effectiveness between its application in the acute and chronic phases, and determine its contribution to preventing the development of PHN. Based on the outcome, the effectiveness of this treatment can be demonstrated.

Procedure: Lidocaine (drug)

Interventions

Lidocaine (drug) PROCEDURE

Lidocain subcuteous infiltratyion will be done to rush area.

Patients who are referred from the dermatology clinic or voluntarily present to our pain management

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• patients over the age of 18
• with acute HZ pain (rash duration \< 30 days
• pain due to PHN (rash duration \> 3 months),

You may not qualify if:

• patients on anticoagulants or have coagulation disorders, patients with psychomotor disorders patients with uncontrolled diabetes patients with bacterial infection or infectious discharge in the affected dermatomal region patients allergic to lidocaine patients with lesions in the facial or genital regions pregnant or breastfeeding patients

Sponsors & Collaborators

• Ankara City Hospital Bilkent: lead

Study Sites (1)

Üniversiteler Mahallesi 1604. Cadde No: 9 Çankaya/ANKARA

Ankara, Cankaya, 06800, Turkey (Türkiye)

Location

Related Publications (1)

• Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG, Labetoulle M, Michel JP, Naldi L, Sanmarti LS, Weinke T. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015 Jul;3(4):109-20. doi: 10.1177/2051013615599151.

  PMID: 26478818 RESULT

MeSH Terms

Conditions

Herpes Zoster; Neuralgia, Postherpetic

Interventions

Lidocaine; Pharmaceutical Preparations

Condition Hierarchy (Ancestors)

Varicella Zoster Virus Infection; Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections; Neuralgia; Peripheral Nervous System Diseases; Neuromuscular Diseases; Nervous System Diseases; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Acetanilides; Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical doctor

Study Record Dates

• First Submitted: March 6, 2025
• First Posted: March 18, 2025
• Study Start: April 1, 2025
• Primary Completion: February 1, 2026
• Study Completion: February 20, 2026
• Last Updated: September 4, 2026

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)